Login Register Cart 0
Generic placeholder image

Current Pediatric Reviews

Editor-in-Chief

ISSN (Print): 1573-3963
ISSN (Online): 1875-6336

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Corticosteroid as an Adjunct in the Treatment of Endobronchial Tuberculosis: A Systematic Review & Meta-analysis

Author(s): Nihar R. Mishra, Manoj K. Panigrahi, Girish C. Bhatt and Rashmi R. Das*

Volume 16, Issue 1, 2020

Page: [53 - 60] Pages: 8

DOI: 10.2174/1573396315666191016100615

Abstract

Background: Corticosteroid exerts anti-inflammatory action and can prevent tissue damage resulting from various causes. Studies have shown that corticosteroids may prevent the damaging effect of tuberculosis (TB) in various organs, but there is no published meta-analysis specifically looking for the effect of corticosteroid in endobronchial TB.

Objective: To synthesize the evidence regarding the usefulness of corticosteroid in endo-bronchial TB.

Methods: A comprehensive search was performed of the major electronic databases till 30th November 2018. Randomized trials comparing treatment with corticosteroid as an adjunct to antitubercular drugs (ATT) versus placebo/no treatment in endobronchial TB were included. Three authors independently applied eligibility criteria, assessed the studies for methodological quality, and extracted data. The review is registered at PROSPERO database [CRD42016047063].

Results: Out of 525 search results, 4 trials including 205 patients (151 children) were eligible for inclusion. Oral prednisolone was used in various dose schedules. Rifampicin containing ATT regimen was used in 3 trials. The bronchoscopy findings showed no significant improvement at 1 month (effect size could not be calculated due to 0 event in the intervention group, p = 0.05), 2 months (RR 1.26, 95% CI 0.89 to 1.8), and at completion of ATT (RR 0.63, 95% CI 0.1 to 4.14) in steroid-treated group compared to the control group. The need for repeat bronchoscopy was significantly decreased in the steroid group (RR 0.13, 95% CI 0.02 to 0.9). Among the adverse events, the infection rate was significantly lesser in the steroid group (RR 0.53, 95% CI 0.29 to 0.97); but other adverse events (mortality, hypertension, and abdominal distension) showed no significant difference between the two groups. The GRADE evidence generated was of very low quality.

Conclusion: The present meta-analysis showed that oral steroid does not help patients with endobronchial tuberculosis. However, the quality of evidence was very low. Future trials with robust design and a larger sample size would be required to provide any firm recommendation regarding the use of oral prednisolone in endobronchial tuberculosis.

Keywords: Mycobacteria, anti-tubercular drugs, prednisolone, children, adults, evidence-based medicine, bronchoscopy.

« Previous Next »
Graphical Abstract

[1]
Floyd K, Glaziou P, Zumla A, Raviglione M. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Lancet Respir Med 2018; 6(4): 299-314.
[http://dx.doi.org/10.1016/S2213-2600(18)30057-2] [PMID: 29595511]
[2]
Shahzad T, Irfan M. Endobronchial tuberculosis-a review. J Thorac Dis 2016; 8(12): 3797-802.
[http://dx.doi.org/10.21037/jtd.2016.12.73] [PMID: 28149579]
[3]
Kashyap S, Solanki A. Challenges in endobronchial tuberculosis: from diagnosis to management. Pulm Med 2014; 2014594806
[http://dx.doi.org/10.1155/2014/594806] [PMID: 25197570]
[4]
Alzeer AH, FitzGerald JM. Corticosteroids and tuberculosis: risks and use as adjunct therapy. Tuber Lung Dis 1993; 74(1): 6-11.
[http://dx.doi.org/10.1016/0962-8479(93)90060-B] [PMID: 8495021]
[5]
Nemir RL, Cardona J, Vaziri F, Toledo R. Prednisone as an adjunct in the chemotherapy of lymph node-bronchial tuberculosis in childhood: a double-blind study. II. Further term observation. Am Rev Respir Dis 1967; 95(3): 402-10.
[PMID: 5335164]
[6]
Toppet M, Malfroot A, Derde MP, Toppet V, Spehl M, Dab I. Corticosteroids in primary tuberculosis with bronchial obstruction. Arch Dis Child 1990; 65(11): 1222-6.
[http://dx.doi.org/10.1136/adc.65.11.1222] [PMID: 2248533]
[7]
Park IW, Choi BW, Hue SH. Prospective study of corticosteroid as an adjunct in the treatment of endobronchial tuberculosis in adults. Respirology 1997; 2(4): 275-81.
[http://dx.doi.org/10.1111/j.1440-1843.1997.tb00089.x] [PMID: 9525297]
[8]
Mo EK, Kim HJ, Choi JE, et al. The effect of corticosteroid on the treatment of endobronchial tuberculosis. Tuberc Respir Dis (Seoul) 1997; 44: 409-18.
[http://dx.doi.org/10.4046/trd.1997.44.2.409]
[9]
Critchley JA, Orton LC, Pearson F. Adjunctive steroid therapy for managing pulmonary tuberculosis. Cochrane Database Syst Rev 2014; (11): CD011370
[http://dx.doi.org/10.1002/14651858.CD011370] [PMID: 25387839]
[10]
Higgins J, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org Chichester: Wiley- Blackwell, 2011.
[11]
Review Manager 2014. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014 (assessed 20th August 2018).
[12]
Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64(4): 383-94.
[http://dx.doi.org/10.1016/j.jclinepi.2010.04.026] [PMID: 21195583]

Rights & Permissions Print Cite
Article Metrics
19
7
© 2024 Bentham Science Publishers | Privacy Policy